Prolonged Survival on PARP Inhibitor Therapy In a Patient With Stage IV Non-small Cell Lung Cancer: A Case Report

Author(s): Ana Lucía González Herrera, Mustafa Al Gburi MD, Ahmed Ayad MD, Julio Peguero MD

A BRCA1 mutation has been identified in a 56-year old female with adenocarcinoma of the lung. Following partial response with Nivolumab therapy, the patient started maintenance therapy with Olaparib, a PolyADP-ribose Polymerase (PARP) inhibitor showing sustained progression free response that is still ongoing.